Kuros Biosciences Receives Approvals in the USA and New Zealand

Schlieren ZH – Kuros Biosciences receives approval in the USA for MagnetOs granules for interbody application. The authorities in New Zealand have granted approval for MagnetOs granules and MagnetOs Putty.

Schlieren-based Kuros Biosciences AG has received market approval from the US Food and Drug Administration (FDA) for the use of MagnetOs-Granules for interbody application, according to a press release. MagnetOs Granules is thus the third product from the MagnetOs portfolio to receive FDA approval for use in intervertebral discs. At the beginning of January, Kuros announced the FDA approval of MagnetOs Easypack Putty for intercorporal use and MagnetOs Putty for standalone use in the posterolateral spine. This means that it can now be used without autograft (patient's own bone).

Kuros also announces the market release of MagnetOs Granules and MagnetOs Putty in New Zealand. The products are now commercially available through Vortek Spine Limited (Vortek), a high-tech orthopaedic and biologics company based in Christchurch.

"We are very pleased that MagnetOs Granules has received marketing authorization for interbody use, as the Granules technology is the foundation of the MagnetOs platform," Chris Fair, CEO of Kuros Biosciences, is quoted as saying. "This approval, in conjunction with the MagnetOs Flex Matrix and MagnetOs Easypack Putty formulas, provides surgeons with the widest range of advanced biologic applications available for use in the intervertebral body." Kuros is expanding its international presence by partnering with Vortek in New Zealand to introduce its clinically proven technology to this region.

Kuros Biosciences AG is a spin-off from the University of Zurich and the Swiss Federal Institute of Technology Zurich. The company is based in the Bio-Technopark Schlieren-Zurich. ce/gba

View full article